Ocular Therapeutix (OCUL) Assets Average (2014 - 2026)
Ocular Therapeutix's quarterly Assets Average came in at $770.3 million in Q1 2026, up 78.34% year-on-year from $431.9 million in Q1 2025, and up 26.39% quarter-over-quarter from $609.5 million in Q4 2025.
Ocular Therapeutix has reported Assets Average for 13 years, with the latest figure at $770.3 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 78.34% year-over-year to $770.3 million; the trailing twelve-month figure through Mar 2026 stood at $770.3 million (up 78.34% YoY), and the FY2025 full-year result was $633.0 million, up 78.31% from the prior year.
- Assets Average for Q1 2026 stood at $770.3 million, up from $609.5 million in the prior quarter.
- The five-year high for Assets Average was $770.3 million in Q1 2026, with the low at $125.6 million in Q2 2023.
- Average Assets Average over 5 years is $346.1 million, with a median of $395.5 million recorded in 2024.
- Year-over-year, Assets Average slumped 30.38% in 2023 and jumped 320.51% in 2024.
- Tracing OCUL's Assets Average over 5 years: stood at $153.9 million in 2022, then soared by 34.62% to $207.2 million in 2023, then soared by 128.81% to $474.2 million in 2024, then increased by 28.54% to $609.5 million in 2025, then advanced by 26.39% to $770.3 million in 2026.
- The last three Assets Average figures came in at $770.3 million (Q1 2026), $609.5 million (Q4 2025), and $431.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn | 770.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 770.29 Mn |
| Dec 31, 2025 | 609.47 Mn |
| Sep 30, 2025 | 431.11 Mn |
| Jun 30, 2025 | 428.63 Mn |
| Mar 31, 2025 | 431.93 Mn |
| Dec 31, 2024 | 474.15 Mn |
| Sep 30, 2024 | 503.73 Mn |
| Jun 30, 2024 | 528.02 Mn |
| Mar 31, 2024 | 395.50 Mn |
| Dec 31, 2023 | 207.22 Mn |
| Sep 30, 2023 | 142.47 Mn |
| Jun 30, 2023 | 125.57 Mn |
| Mar 31, 2023 | 138.93 Mn |
| Dec 31, 2022 | 153.93 Mn |
| Sep 30, 2022 | 165.83 Mn |
| Jun 30, 2022 | 180.35 Mn |
| Mar 31, 2022 | 196.25 Mn |
| Dec 31, 2021 | 211.31 Mn |
| Sep 30, 2021 | 224.22 Mn |
| Jun 30, 2021 | 236.87 Mn |
| Mar 31, 2021 | 252.45 Mn |
| Dec 31, 2020 | 180.04 Mn |
| Sep 30, 2020 | 102.74 Mn |
| Jun 30, 2020 | 90.06 Mn |
| Mar 31, 2020 | 75.80 Mn |
| Dec 31, 2019 | 83.73 Mn |
| Sep 30, 2019 | 89.23 Mn |
| Jun 30, 2019 | 95.62 Mn |
| Mar 31, 2019 | 87.27 Mn |
| Dec 31, 2018 | 71.66 Mn |
| Sep 30, 2018 | 70.36 Mn |
| Jun 30, 2018 | 73.57 Mn |
| Mar 31, 2018 | 66.06 Mn |
| Dec 31, 2017 | 59.92 Mn |
| Sep 30, 2017 | 72.04 Mn |
| Jun 30, 2017 | 85.19 Mn |
| Mar 31, 2017 | 82.82 Mn |
| Dec 31, 2016 | 78.64 Mn |
| Sep 30, 2016 | 86.12 Mn |
| Jun 30, 2016 | 95.17 Mn |
| Mar 31, 2016 | 105.37 Mn |
| Dec 31, 2015 | 114.81 Mn |
| Sep 30, 2015 | 124.39 Mn |
| Jun 30, 2015 | 100.48 Mn |
| Mar 31, 2015 | 74.85 Mn |
| Dec 31, 2014 | 81.04 Mn |
| Sep 30, 2014 | 53.93 Mn |